Article Versions Notes

Sakamoto S, Maimaiti M, Xu M, Kamada S, Yamada Y, Kitoh H, Matsumoto H, Takeuchi N, Higuchi K, Uchida HA, et al. Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. Journal of Clinical Medicine. 2019; 8(4):489. https://doi.org/10.3390/jcm8040489

Sakamoto, Shinichi, Maihulan Maimaiti, Minhui Xu, Shuhei Kamada, Yasutaka Yamada, Hiroki Kitoh, Hiroaki Matsumoto, Nobuyoshi Takeuchi, Kosuke Higuchi, Haruhito A. Uchida, and et al. 2019. "Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer" Journal of Clinical Medicine 8, no. 4: 489. https://doi.org/10.3390/jcm8040489

Sakamoto, S., Maimaiti, M., Xu, M., Kamada, S., Yamada, Y., Kitoh, H., Matsumoto, H., Takeuchi, N., Higuchi, K., Uchida, H. A., Komiya, A., Nagata, M., Nakatsu, H., Matsuyama, H., Akakura, K., & Ichikawa, T. (2019). Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. Journal of Clinical Medicine, 8(4), 489. https://doi.org/10.3390/jcm8040489